ArticleGlobal health research and policy2025
Aggregate distributional cost-effectiveness analysis: a novel tool for health economic evaluation to inform resource allocation.
Article in Global health research and policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methodological heterogeneity and equity challenges of distributional cost-effectiveness analysis in healthcare: a systematic review from 2017 to 2025.Archives of public health = Archives belges de sante publique · 2026Pooled it
- Channel Allocation and Equity in Preventive Campaigns for Older Adults: Agent-Based Modeling Study.Journal of medical Internet research · 2026Article
- Estimating the economic burden of lower respiratory infections in China from 2020 to 2040: a health-augmented macroeconomic modelling study.The Lancet regional health. Western Pacific · 2026Article
- How policymakers value end-of-life treatments for rare and common diseases in China: evidence from a contingent valuation study.Global health research and policy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Health equity is a growing concern for policymakers across the globe. Conventional cost-effectiveness analysis (CEA), commonly used in evaluating health interventions, primarily focuses on the average and aggregate health outcomes in the targeted population, neglecting the distributional impacts on health equity. This gap calls for approaches that can quantify the impact of intervention of interest on health equity to support decision-making. Distributional Cost-Effectiveness Analysis (DCEA) offers a framework to assess the distributional impacts of health interventions. Based on DCEA, aggregate DCEA (A-DCEA) was proposed as a practical and simplified alternative to DCEA. Unlike full DCEA, which requires detailed subgroup data, A-DCEA utilizes aggregated data, making it accessible and feasible for broader use. In this commentary, we discuss the rationale for A-DCEA, outline the steps for its implementation, and highlight its applicability. The purpose of this article is to introduce A-DCEA as a pragmatic and accessible tool for evaluating the equity implications of healthcare interventions. A-DCEA can inform policymakers by incorporating equity considerations into healthcare decision-making, particularly when conducting a full DCEA is impractical due to data limitation. A-DCEA provides a valuable and accessible method for evaluating the distributional impact of interventions, promoting health equity in decision-making. Its adoption can lead to more informed health policy that considers health inequities as well as the efficient use of resources.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.